Article Details
Retrieved on: 2024-02-03 13:38:15
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details successful outcomes of the VARIPULSETM Platform clinical trials by Biosense Webster Inc. for treating atrial fibrillation, highlighting an 80% success rate in preventing arrhythmia recurrence. The studies demonstrate the platform's efficacy and safety within global markets, with a focus on cardiology and electrophysiology.
Article found on: menafn.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here